Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $8.85, but opened at $10.02. Abivax shares last traded at $9.56, with a volume of 1,030,752 shares trading hands.
Analyst Ratings Changes
A number of analysts have recently issued reports on ABVX shares. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price target on shares of Abivax in a report on Wednesday, April 30th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price target on shares of Abivax in a report on Thursday, March 20th.
Check Out Our Latest Report on ABVX
Abivax Trading Up 11.6%
The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.29. The business's fifty day moving average is $7.01 and its 200-day moving average is $6.76.
Hedge Funds Weigh In On Abivax
A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in Abivax during the 4th quarter worth approximately $5,336,000. Franklin Resources Inc. raised its stake in Abivax by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock worth $10,732,000 after acquiring an additional 141,710 shares during the period. Springhill Fund Asset Management HK Co Ltd bought a new stake in Abivax during the 4th quarter worth approximately $1,520,000. ADAR1 Capital Management LLC raised its stake in Abivax by 190.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock worth $11,078,000 after acquiring an additional 991,781 shares during the period. Finally, Kennedy Capital Management LLC raised its stake in Abivax by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock worth $1,650,000 after acquiring an additional 1,656 shares during the period. Hedge funds and other institutional investors own 47.91% of the company's stock.
Abivax Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
